Advocacy intelligence hub — real-time data for patient organizations
M.D. Anderson Cancer Center — PHASE2
M.D. Anderson Cancer Center — PHASE1
Pepaxto: FDA approved
Treatment, in combination with dexamethasone, of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody (Indication withdrawn)
National Human Genome Research Institute (NHGRI)
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Pepaxto
Oncopeptides AB
Patient Assistance Programs1
Neulasta
Amgen, Inc.
Bosulif
(bosutinib)Orphan drugstandardPF PRISM C.V.
12.1 Mechanism of Action Bosutinib is a TKI. Bosutinib inhibits the BCR-ABL kinase that promotes CML; it is also an inhibitor of Src-family kinases in...
Browse all Familial platelet disorder with associated myeloid malignancy news →
Chitra Hosing, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Paul Liu, M.D.
National Human Genome Research Institute (NHGRI)
Joie Davis
National Human Genome Research Institute
Erica Bresciani
National Human Genome Research Institute
Paul P Liu
National Human Genome Research Institute
Panagiotis Baliakas
Uppsala University
View all Familial platelet disorder with associated myeloid malignancy specialists →